Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Clonal chromosomal abnormalities appearing in Philadelphia chromosome–negative metaphases during CML treatment

Ghayas C. Issa, Hagop M. Kantarjian, Graciela Nogueras Gonzalez, Gautam Borthakur, Guilin Tang, William Wierda, Koji Sasaki, Nicholas J. Short, Farhad Ravandi, Tapan Kadia, Keyur Patel, Raja Luthra, Alessandra Ferrajoli, Guillermo Garcia-Manero, Mary Beth Rios, Sara Dellasala, Elias Jabbour, Jorge E. Cortes

Blood (2017) 130 (19): 2084–2091.

https://doi.org/10.1182/blood-2017-07-792143

Published: 2017

Includes: Supplemental data

Journal Articles

Prediction for Sustained Deep Molecular Response of BCR-ABL Levels in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Susan O'Brien, MD, Farhad Ravandi, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Naval Daver, MD, Alessandra Ferrajoli, MD, Koichi Takahashi, MD, Preetesh Jain, MBBS, MDDM, PhD, Mary Beth Rios, RN, Sherry Pierce, BSN, BA, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2016) 128 (22): 1224.

https://doi.org/10.1182/blood.V128.22.1224.1224

Published: 2016

Journal Articles

CML Patients Outcome after TKI Discontinuation: A Single Institution Experience in the US

Kamal Chamoun, MD, Hagop M. Kantarjian, MD, Mary Beth Rios, RN, Rita Assi, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Nitin Jain, MD, Naval Daver, MD, Marina Konopleva, MD PhD, Courtney D DiNardo, MD, Tapan M. Kadia, MD, Naveen Pemmaraju, MD, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2016) 128 (22): 1923.

https://doi.org/10.1182/blood.V128.22.1923.1923

Published: 2016

Journal Articles

Clinical Application of Artificial Intelligence in Patients with Chronic Myeloid Leukemia in Chronic Phase

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Susan O'Brien, MD, Farhad Ravandi, MD, Marina Konopleva, MDPhD, Gautam Borthakur, MD, William G. Wierda, MD PhD, Naval Daver, MD, Koichi Takahashi, MD, Preetesh Jain, MBBS,MDDM,PhD, Jeffrey Skinner, Mary Beth Rios, RN, Sherry Pierce, BSN, BA, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD

Blood (2016) 128 (22): 940.

https://doi.org/10.1182/blood.V128.22.940.940

Published: 2016

Journal Articles

Patient (Pt)-Driven Discontinuation of Tyrosine Kinase Inhibitor Theray in Chronic Phase Chronic Myeloid Leukemia (CML) - Single Institution Experience

Ohad Benjamini, MD, Hagop M. Kantarjian, MD, Mary Beth Rios, RN, Elias Jabbour, MD, Susan O'Brien, M.D., Preetesh Jain, MD, DM, PhD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Gautam Borthakur, M.D., Alfonso Quintás-Cardama, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3783.

https://doi.org/10.1182/blood.V120.21.3783.3783

Published: 2012

Journal Articles

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

Hagop Kantarjian, Susan O'Brien, Elias Jabbour, Guillermo Garcia-Manero, Alfonso Quintas-Cardama, Jenny Shan, Mary Beth Rios, Farhad Ravandi, Stefan Faderl, Tapan Kadia, Gautam Borthakur, Xuelin Huang, Richard Champlin, Moshe Talpaz, Jorge Cortes

Blood (2012) 119 (9): 1981–1987.

https://doi.org/10.1182/blood-2011-08-358135

Published: 2012

Journal Articles

Improved Survival in Chronic Myeloid Leukemia (CML) Since the Introductin of Imatinib Therapy - A Single Institution Historical Experience

Hun Lee, MD, Jorge E. Cortes, Susan O'Brien, MD, Elias Jabbour, Guillermo Garcia-Manero, Alfonso Quintas-Cardama, MD, Jenny Shan, PhD, Mary Beth Rios, RN, Farhad Ravandi, MD, Stefan Faderl, MD, Tapan Kadia, Gautam Borthakur, Xuelin Huang, PhD, Hagop M. Kantarjian

Blood (2011) 118 (21): 2750.

https://doi.org/10.1182/blood.V118.21.2750.2750

Published: 2011

Journal Articles

Inotuzumab Ozogamycin (I0), a CD22 Monoclonal Antibody Conjugated to Calecheamicin, Is Active in Refractory-Relapse Acute Lymphocytic Leukemia (R-R ALL)

Susan o'Brien, Deborah A. Thomas, MD, Maro Ohanian, M.D., Jeffrey L. Jorgensen, MD, PhD, Partow Kebriaei, MD, Elias Jabbour, Michael E. Rytting, MD, Sergernne York, RN, Farhad Ravandi, MD, Monica Kwari, BSN, Stefan Faderl, MD, Mary Beth Rios, RN, Jorge E. Cortes, Luis Fayad, MD, Robert Tarnai, MT, Sa A. Wang, MD, Richard Champlin, MD, Anjali S. Advani, MD, Hagop M. Kantarjian

Blood (2011) 118 (21): 875.

https://doi.org/10.1182/blood.V118.21.875.875

Published: 2011

Journal Articles

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

Elias Jabbour, Hagop Kantarjian, Susan O'Brien, Jenny Shan, Alfonso Quintas-Cardama, Stefan Faderl, Guillermo Garcia-Manero, Farhad Ravandi, Mary Beth Rios, Jorge Cortes

Blood (2011) 118 (17): 4541–4546.

https://doi.org/10.1182/blood-2011-04-348110

Published: 2011

Journal Articles

Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies

Dushyant Verma, Hagop Kantarjian, Sara S. Strom, Mary Beth Rios, Elias Jabbour, Alfonso Quintas-Cardama, Srdan Verstovsek, Farhad Ravandi, Susan O'Brien, Jorge Cortes

Blood (2011) 118 (16): 4353–4358.

https://doi.org/10.1182/blood-2011-06-362889

Published: 2011

Journal Articles

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure

Elias Jabbour, Hagop Kantarjian, Susan O'Brien, Jenny Shan, Guillermo Garcia-Manero, William Wierda, Farhad Ravandi, Gautam Borthakur, Mary Beth Rios, Jorge Cortes

Blood (2011) 117 (6): 1822–1827.

https://doi.org/10.1182/blood-2010-07-293977

Published: 2011

Journal Articles

Uncommon BCR-ABL kinase domain mutations in kinase inhibitor–resistant chronic myelogenous leukemia and Ph + acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects

Dan Jones, Su S. Chen, Elias Jabbour, Mary Beth Rios, Hagop Kantarjian, Jorge Cortes

Blood (2010) 115 (26): 5428–5429.

https://doi.org/10.1182/blood-2009-11-252155

Published: 2010

Includes: Supplemental data

Journal Articles

Predictive Factors for Response and Outcome in Patients (pts) Treated with Second Generation Tyrosine Kinase Inhibitors (2-TKI) for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Post Imatinib Failure.

Elias Jabbour, MD, Hagop Kantarjian, MD, Susan O'Brien, MD, Jenny Shan, PhD, Guillermo Garcia-Manero, MD, William Wierda, MD, PhD, Farhad Ravandi, MD, Gautam Borthakur, MD, Mary Beth Rios, RN, Jorge Cortes, MD

Blood (2009) 114 (22): 509.

https://doi.org/10.1182/blood.V114.22.509.509

Published: 2009

Journal Articles

Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): a Target Worth Aiming and Achieving?.

Dushyant Verma, MD, FACP, Hagop M Kantarjian, MD, Jenny Shan, PhD, Susan O'Brien, MD, Amit Verma, MD, Elias Jabbour, MD, Srdan Verstovsek, MD, PhD, Tapan Kadia, MD, Mary Beth Rios, RN, Jorge Cortes, MD

Blood (2009) 114 (22): 505.

https://doi.org/10.1182/blood.V114.22.505.505

Published: 2009

Journal Articles

Causes of Death for Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Imatinib.

Andrea Renata Dean, MD, Hagop M. Kantarjian, MD, Susan O'Brien, MD, Mary Beth Rios, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Jianqin Shan, Ph.D, Jorge Cortes, MD

Blood (2009) 114 (22): 4279.

https://doi.org/10.1182/blood.V114.22.4279.4279

Published: 2009

Journal Articles

Phase I Study of Bendamustine in Refractory Leukemia.

Mary Beth Rios, RN, Elias Jabbour, MD, Farhad Ravandi, M.D., Tapan Kadia, MD, Zeev Estrov, MD, Gautam Borthakur, MD, Elizabeth Burton, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 4156.

https://doi.org/10.1182/blood.V114.22.4156.4156

Published: 2009

Journal Articles

Chronic myeloid leukemia (CML) with P190 BCR-ABL : analysis of characteristics, outcomes, and prognostic significance

Dushyant Verma, Hagop M. Kantarjian, Dan Jones, Rajyalakshmi Luthra, Gautam Borthakur, Srdan Verstovsek, Mary Beth Rios, Jorge Cortes

Blood (2009) 114 (11): 2232–2235.

https://doi.org/10.1182/blood-2009-02-204693

Published: 2009

Journal Articles

Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase

Carmen Fava, Hagop M. Kantarjian, Elias Jabbour, Susan O'Brien, Nitin Jain, Mary Beth Rios, Guillermo Garcia-Manero, Farhad Ravandi, Srdan Verstovsek, Gautam Borthakur, Jianqin Shan, Jorge Cortes

Blood (2009) 113 (21): 5058–5063.

https://doi.org/10.1182/blood-2008-10-184960

Published: 2009

Journal Articles

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

Elias Jabbour, Hagop M. Kantarjian, Dan Jones, Jenny Shan, Susan O'Brien, Neeli Reddy, William G. Wierda, Stefan Faderl, Guillermo Garcia-Manero, Srdan Verstovsek, Mary Beth Rios, Jorge Cortes

Blood (2009) 113 (10): 2154–2160.

https://doi.org/10.1182/blood-2008-04-154344

Published: 2009

Journal Articles

Significance of Rising Levels of Minimal Residual Disease in Patients with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (Ph+ CML) in Complete Cytogenetic Response (CGCR)

Hagop M Kantarjian, Jianqin Shan, Dan Jones, Susan O’Brien, Mary Beth Rios, Elias Jabbour, Jorge Cortes

Blood (2008) 112 (11): 445.

https://doi.org/10.1182/blood.V112.11.445.445

Published: 2008

NARROW

Clonal chromosomal abnormalities appearing in Philadelphia chromosome–negative metaphases during CML treatment

Prediction for Sustained Deep Molecular Response of BCR-ABL Levels in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

CML Patients Outcome after TKI Discontinuation: A Single Institution Experience in the US

Clinical Application of Artificial Intelligence in Patients with Chronic Myeloid Leukemia in Chronic Phase

Patient (Pt)-Driven Discontinuation of Tyrosine Kinase Inhibitor Theray in Chronic Phase Chronic Myeloid Leukemia (CML) - Single Institution Experience

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

Improved Survival in Chronic Myeloid Leukemia (CML) Since the Introductin of Imatinib Therapy - A Single Institution Historical Experience

Inotuzumab Ozogamycin (I0), a CD22 Monoclonal Antibody Conjugated to Calecheamicin, Is Active in Refractory-Relapse Acute Lymphocytic Leukemia (R-R ALL)

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure

Uncommon BCR-ABL kinase domain mutations in kinase inhibitor–resistant chronic myelogenous leukemia and Ph + acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects

Predictive Factors for Response and Outcome in Patients (pts) Treated with Second Generation Tyrosine Kinase Inhibitors (2-TKI) for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Post Imatinib Failure.

Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): a Target Worth Aiming and Achieving?.

Causes of Death for Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Imatinib.

Phase I Study of Bendamustine in Refractory Leukemia.

Chronic myeloid leukemia (CML) with P190 BCR-ABL : analysis of characteristics, outcomes, and prognostic significance

Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

Significance of Rising Levels of Minimal Residual Disease in Patients with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (Ph+ CML) in Complete Cytogenetic Response (CGCR)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only